Strata Skin Sciences (FRA:E2O) Beneish M-Score: -3.37 (As of Jun. 27, 2026)

What is Strata Skin Sciences Beneish M-Score?

Strata Skin Sciences FRA:E2O 38 Beneish M-Score is -3.37 as of Jun. 27, 2026. GuruFocus rates FRA:E2O with a GF Score™ of 38/100 and a GF Value™ of €56.54. The stock has 5 warning signs investors should review. Among 766 Medical Devices & Instruments companies, Strata Skin Sciences ranks better than 86.42% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.37 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Strata Skin Sciences's Beneish M-Score or its related term are showing as below:

FRA:E2O' s Beneish M-Score Range Over the Past 10 Years
Min: -3.65 Med: -3.43 Max: -2.45
Current: -3.37

During the past 13 years, the highest Beneish M-Score of Strata Skin Sciences was -2.45. The lowest was -3.65. And the median was -3.43.

Strata Skin Sciences Beneish M-Score Related Terms

Strata Skin Sciences Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Strata Skin Sciences's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Strata Skin Sciences Beneish M-Score Chart

Strata Skin Sciences Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Beneish M-Score

Get a 7-Day Free Trial

-2.88

-2.45

-3.55

-3.50

-3.37

Strata Skin Sciences Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
Beneish M-Score	Get a 7-Day Free Trial															-3.50	-3.27	-3.56	-3.72	-3.37

FRA:E2O vs IRME, NUMD, WOK: Beneish M-Score Comparison

For the Medical Devices subindustry, Strata Skin Sciences's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Strata Skin Sciences Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Strata Skin Sciences's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Strata Skin Sciences's Beneish M-Score falls into.

Save Embed

38GF Score

Strata Skin Sciences Inc FRA:E2O

Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Strata Skin Sciences Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Strata Skin Sciences for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 * 0.815

0.528 * 0.9864

0.404 * 0.8226

0.892 * 0.8606

0.115 * 0.9849

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 * 1.1058

4.679 * -0.126185

0.327 * 1.0638

-3.48

This Year (Dec25) TTM:

Last Year (Dec24) TTM:

Total Receivables was €3.52 Mil.
Revenue was 7.935 + 5.904 + 6.644 + 6.301 = €26.78 Mil.
Gross Profit was 4.794 + 3.565 + 3.733 + 3.373 = €15.47 Mil.
Total Current Assets was €13.32 Mil.
Total Assets was €26.07 Mil.
Property, Plant and Equipment(Net PPE) was €8.44 Mil.
Depreciation, Depletion and Amortization(DDA) was €3.92 Mil.
Selling, General, & Admin. Expense(SGA) was €20.44 Mil.
Total Current Liabilities was €22.84 Mil.
Long-Term Debt & Capital Lease Obligation was €0.59 Mil.
Net Income was 0.05 + -1.382 + -2.158 + -2.25 = €-5.74 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = €0.00 Mil.
Cash Flow from Operations was -0.204 + -0.055 + -1.683 + -0.509 = €-2.45 Mil.

Total Receivables was €5.02 Mil.
Revenue was 9.145 + 7.926 + 7.836 + 6.214 = €31.12 Mil.
Gross Profit was 5.504 + 4.763 + 4.624 + 2.834 = €17.73 Mil.
Total Current Assets was €15.85 Mil.
Total Assets was €33.36 Mil.
Property, Plant and Equipment(Net PPE) was €10.82 Mil.
Depreciation, Depletion and Amortization(DDA) was €4.92 Mil.
Selling, General, & Admin. Expense(SGA) was €21.48 Mil.
Total Current Liabilities was €12.79 Mil.
Long-Term Debt & Capital Lease Obligation was €15.39 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(3.519 / 26.784)	/	(5.017 / 31.121)
	=	0.131384	/	0.161209
	=	0.815

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(17.725 / 31.121)	/	(15.465 / 26.784)
	=	0.569551	/	0.577397
	=	0.9864

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (13.322 + 8.441) / 26.065)	/	(1 - (15.848 + 10.815) / 33.356)
	=	0.165049	/	0.200654
	=	0.8226

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	26.784	/	31.121
	=	0.8606

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(4.915 / (4.915 + 10.815))	/	(3.922 / (3.922 + 8.441))
	=	0.31246	/	0.317237
	=	0.9849

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(20.442 / 26.784)	/	(21.479 / 31.121)
	=	0.763217	/	0.690177
	=	1.1058

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((0.588 + 22.837) / 26.065)	/	((15.386 + 12.793) / 33.356)
	=	0.898715	/	0.844796
	=	1.0638

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(-5.74 - 0	-	-2.451)	/	26.065
	=	-0.126185

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Strata Skin Sciences has a M-score of -3.48 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →

What does a Beneish M-Score of -3.37 mean?

Strata Skin Sciences (FRA:E2O) has a Beneish M-Score of -3.37 as of Jun. 27, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Strata Skin Sciences and its competitors. According to the industry distribution chart, Strata Skin Sciences ranks #104 out of 766 companies in the Medical Devices & Instruments industry, placing it in the top 13.6%.

Is Strata Skin Sciences' Beneish M-Score too high?

Strata Skin Sciences' current Beneish M-Score is -3.37. Based on the distribution chart, Strata Skin Sciences ranks #104 out of 766 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Strata Skin Sciences has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.

How does Strata Skin Sciences' Beneish M-Score compare to IRME and NUMD?

According to the Medical Devices & Instruments industry distribution chart, Strata Skin Sciences ranks #104 out of 766 companies for Beneish M-Score. This places Strata Skin Sciences in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Beneish M-Score for a Medical Devices & Instruments company?

A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Beneish M-Score mean?

A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Strata Skin Sciences and its competitors. Strata Skin Sciences's current Beneish M-Score is -3.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Strata Skin Sciences stock overvalued right now?

Strata Skin Sciences (FRA:E2O) has a current Beneish M-Score of -3.37. The stock's GF Value™ is €56.54, compared to a current price of €3.76 — trading 93.3% below its estimated fair value. The current Beneish M-Score is -3.37. Strata Skin Sciences' overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Beneish M-Score calculated?

Beneish M-Score is calculated from a company's financial statements. For Strata Skin Sciences (FRA:E2O), the current Beneish M-Score is -3.37 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Strata Skin Sciences (FRA:E2O) Overvalued in 2026?

Based on GuruFocus' analysis, Strata Skin Sciences stock appears to be undervalued. The current stock price of €3.76 is trading 93.3% below its estimated GF Value™ of €56.54.

Key valuation signals for FRA:E2O:

Beneish M-Score: -3.37
GF Value™: €56.54 vs. price of €3.76 (93.3% below fair value)
GF Score™: 38/100 with 5 warning signs

No single metric tells the full story. See the FRA:E2O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Strata Skin Sciences Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies IRME NUMD WOK ESMC PFSA ODYY NUWE BJDX VYCO VTAK ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA

Other Exchanges SSKN:USA

Address 5 Walnut Grove Drive, Suite 140, Horsham, PA, USA, 19044

Website https://www.strataskinsciences.com

Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo, and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures, which is the key revenue driver, and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United States.

38GF Score

Get the complete analysis for FRA:E2O

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.76

Price

€56.54

GF Value

View FRA:E2O Analysis

See Beneish M-Score data for all stocks →